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Abstract
Background: Varicella Zoster Virus Immediate Early 63 protein (IE63) has been shown to be
essential for VZV replication, and critical for latency establishment. The activity of the protein as a
transcriptional regulator is not fully clear yet. Using transient transfection assays, IE63 has been
shown to repress viral and cellular promoters containing typical TATA boxes by interacting with
general transcription factors.
Results: In this paper, IE63 regulation properties on endogenous gene expression were evaluated
using an oligonucleotide-based micro-array approach. We found that IE63 modulates the
transcription of only a few genes in HeLa cells including genes implicated in transcription or
immunity. Furthermore, we showed that this effect is mediated by a modification of RNA POL II
binding on the promoters tested and that IE63 phosphorylation was essential for these effects. In
MeWo cells, the number of genes whose transcription was modified by IE63 was somewhat higher,
including genes implicated in signal transduction, transcription, immunity, and heat-shock signalling.
While IE63 did not modify the basal expression of several NF-κB dependent genes such as IL-8,
ICAM-1, and IκBα, it modulates transcription of these genes upon TNFα induction. This effect was
obviously correlated with the amount of p65 binding to the promoter of these genes and with
histone H3 acetylation and HDAC-3 removal.
Conclusion:  While IE63 only affected transcription of a small number of cellular genes, it
interfered with the TNF-inducibility of several NF-κB dependent genes by the accelerated
resynthesis of the inhibitor IκBα.
Background
Varicella Zoster Virus (VZV) is the etiological agent of two
clinically distinct diseases: varicella (chicken pox) as pri-
mary infection and zoster (shingles) after reactivation of
latent virus from the dorsal root ganglia. Zoster is usually
observed in elderly or immuno-compromised patients
[1]. During latency, VZV does not express LAT as other α-
Herpesvirus do, but viral proteins that are also present
during lytic infection [2]. Transcripts from ORF4, 21, 29,
62, 63, and 66 [2-8], and several of the corresponding pro-
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teins have been detected in latently infected cells [8-12]. A
recent study indicated that the expression of latency-
related VZV genes, like ORF62 and 63, is regulated by epi-
genetic modifications of chromatin [13].
IE63 is of particular interest in VZV pathogenesis since it
is abundantly expressed during acute infection and is the
most abundant and most frequently identified of the six
VZV gene products expressed during latency (reviewed in
[14]). Its cellular localization is quite particular. Indeed,
during a lytic infection it localizes mostly in the nucleus
and slightly in the cytoplasm while during latency, it con-
centrates in the cytoplasm [8-10,15]. This protein is
encoded by ORF63 and ORF70 and is the putative homo-
logue of HSV ICP22. It has an apparent molecular mass of
45 kDa and is present in the virion tegument [16]. More-
over, IE63 interacts with VZV IE62 protein [5,17], is essen-
tial or not for VZV replication, depending on the cell-type
studied [5,18,19] and critical for the establishment of
latency [19]. In addition to regulatory functions, evi-
dences were also provided that ORF63 promotes neuronal
cell survival after VZV infection by modulating apopflsfto
κis [20]. It has also been recently shown that expression of
IE63 in the absence of other viral proteins blocked the
antiviral effects of IFN-alpha by inhibiting phosphoryla-
tion of the alpha subunit of eukaryotic initiation factor 2
(eIF-2alpha) [21].
The activity of IE63 as a potential transcriptional regulator
has been subject to controversy for years. It has been
claimed that IE63 played only a minor role in the control
of VZV gene expression [22]. However results from our
laboratory showing that IE63 is able to down-regulate the
expression of VZV immediate early (IE) and early (E)
genes as well as heterologous viral and cellular promoters
[23] suggest that IE63 has essential functions in the virus
infectious cycle. Moreover, these repressive properties
were shown to be dependent on the phosphorylation sta-
tus of the protein [24,25]. Others found that IE63 could
act as a co-stimulator of IE62 activity on the promoter of
the VZV glycoprotein I (gI) [17]. It was alsoshown that
IE63 could activate transcription driven by the cellular EF-
1α promoter in the absence of other viral proteins in non-
neuronal cells [26]. Finally, Desloges et al. added to the
list of promoters regulated by IE63 one other heterolo-
gous promoter, the human GAPDH promoter [27]. Thus,
based on currently published data, the effects of IE63
appear to be pleiotropic depending at least in part of the
cell type and the promoter investigated.
The mechanisms by which IE63 could modulate gene
transcription was poorly understood before it was shown
that IE63 could mediate its repressive properties by disor-
ganizing the pre-initiation complex by interacting with
TFIIH, TFIIE, and RNA POL II [23]. In order to better
understand the mechanism of action of IE63, we exam-
ined its effects on the regulation of cellular genes expres-
sion by full genome micro-array analysis in HeLa and
MeWo cells infected with a lentivirus allowing the stable
expression. We found that IE63 alone affected the tran-
scription of a limited set of human genes. Furthermore,
we showed that in HeLa cells the correct phosphorylation
of IE63 is essential for the regulatory properties on endog-
enous promoters. Recently, a micro-array analysis of
MRC5 cells infected with a recombinant adenovirus
expressing IE63 has been published [28]. In this work,
IE63 was shown to down-regulate the heat shock 70 kDa
protein gene expression while several histone genes were
found up-regulated.
In transient transfection assays, IE63 was demonstrated to
down-regulate several cellular NF-κB-responding genes
like IL-8 and IL-6 [23]. Surprisingly, these genes were not
repressed in our experiments, as demonstrated by both
micro-array analysis and real-time PCR. The fact that IE63
had no effect on basal expression of some NF-κB respon-
sive genes may be due to a problem of promoter accessi-
bility linked to chromatin opening. In order to assess this
issue, we measured the expression rate of some of these
genes (IL-8, IL-6, ICAM-1, and IκBα) in IE63 expressing
HeLa cells after treatment with TNFα, a major pro-inflam-
matory cytokine known to increase chromatin accessibil-
ity of several promoters. We demonstrated that IE63
modulated IL-8, ICAM-1, and IκBα expression in response
to TNFα via chromatin remodelling and modification of
the recruitment of NF-κB p65 subunit.
Results
Varicella Zoster Virus IE63 protein affects transcription of 
a small number of genes in HeLa cells
In order to study the influence of IE63 on human cellular
transcription, three independent stable HeLa cell lines
expressing IE63 protein were established. The whole
genome expression profiles of HeLa cells infected with a
recombinant lentivirus expressing VZV ORF63 (HeLa-
IE63) and of HeLa cells infected with a recombinant len-
tivirus where IE63 gene was cloned in an inverted orienta-
tion (HeLa-Inv) were compared. In the lentivirus vectors
used, the VZV gene was controlled by the EFIα promoter
and was in frame with the EGPF gene but separated by an
IRES region. All infections were carried out with the same
multiplicity of infection. As expected, the three HeLa cell
lines infected with the LentiIE63 (HeLa-IE63) expressed
the EGFP protein (lower panel) and a protein of approxi-
mately 45 kDa recognized by a mouse monoclonal anti-
body directed against the VZV ORF63 protein (Fig.1A).
IE63 was not detected in the three HeLa cell lines infected
with the lentivirus where the ORF63 was cloned in the
anti-sense direction (HeLa-Inv, control cells). Virtually
100% of HeLa cells expressed EGFP as determined by flowBMC Molecular Biology 2007, 8:99 http://www.biomedcentral.com/1471-2199/8/99
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cytometry analysis (data not shown). Immunofluores-
cence studies were carried out to evaluate the proportion
of HeLa cells expressing IE63 protein, and 100% of the
cells expressing the EGFP protein also expressed IE63 (Fig.
1B).
Because the correct phosphorylation of IE63 was found
essential for its repressive properties in transient transfec-
tion studies [24,25], HeLa cells stably expressing mutated
forms of IE63 were generated : HeLa-IE63-S224/T222A,
where two essential CDK1 phosphorylation residues
(S224 and T222) were substituted by alanine [24], and
HeLa-IE63-Full where all the phosphorylation target resi-
dues for CK1, CK2, and CDK1 were substituted by anala-
line [24]. The expression level and the proportion of cells
expressing the mutated forms of IE63 protein were veri-
fied (Fig.1A, and 1B). The regulation properties of these
mutated proteins on cellular genes were analyzed by real-
time RT-PCR. As shown in Fig. 2, the abolition of phos-
phorylation drastically reduces the up- or down-regulat-
ing properties of IE63 on selected genes demonstrating
that phosphorylation is essential for its activity on endog-
enous promoters.
To control whether IE63 was functional, HeLa cell lines
expressing wild-type IE63 were transfected with a plasmid
expressing a reporter gene (luciferase) under the control
of the VZV DNA polymerase promoter which displayed a
VZV ORF 63 activity and expression by Lentivirus Figure 1
VZV ORF 63 activity and expression by Lentivirus. HeLa cells were infected with the lentivirus (Lenti-IE63, Lenti-Inv, Lenti-
IE63-S224/T222A, Lenti-IE63-Full) in order to generate cell lines that stably express the protein IE63 wild-type (HeLa-IE63), in 
inverted orientation (HeLa-Inv) or mutated (HeLa-S224/T222A, HeLa-Full). One week after infection, cells were harvested. (A) 
Cells were lysed in radioimmunoprecipitation assay buffer and used for immunoblotting with mouse monoclonal antibody to 
the ORF63 protein or with rabbit polyclonal antibody to the EGFP. (B) Forty-eight hours post-seeding, immunostaining analysis 
was carried out using a monoclonal antibody (9A12) directed against IE63. Secondary antibody used is conjugated with Texas 
Red. (C) HeLa cells (HeLa-IE63, and HeLa-Inv) were transfected with 1 µg of pPol-Luc. 24 hours post-transfection, cells were 
harvested and the reporter gene activity was measured. Results are presented as a percentage of stimulation with respect to 
the basal expression of the promoter (= 100%). Data from luciferase assays were collected from six independent transfection 
experiments. ρ-values were calculated using the graphpad quickcalcs software [59]: *, significantly different from control (p-
value < 0.05).
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Relative expression of selected cellular genes in HeLa-IE63, HeLa-IE63-S224/T222A, HeLai-IE63-Full versus control cells  (HeLa-Inv) Figure 2
Relative expression of selected cellular genes in HeLa-IE63, HeLa-IE63-S224/T222A, HeLai-IE63-Full versus control 
cells (HeLa-Inv). mRNA levels (A : RCE1, C3, RAB8B, and GATA3 ; B : CYFIP2, GPR37, WIF1, and NELL2) were determined 
by quantitative real-time PCR and normalized using the β2-microglobuline transcripts. Experiments were done at least in tripli-
cate. Differences (n-fold) between samples were calculated using the standard-curve method and the 2-∆Ct method. ρ-values 
were calculated using the graphpad quickcalcs software [59] : *, significantly different from control (Inv ; p-value < 0.05) ; **, 
not significantly different from control (Inv ; p-value ≥ 0.05).
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high basal activity and is known to be down-regulated by
IE63 [25]. As shown in Fig. 1C, the basal activity of this
promoter is down-regulated up to 50% in cells expressing
IE63, demonstrating that IE63 is functional in these cells.
These cell lines expressing the wild-type IE63 protein were
used for a micro-array analysis to delineate the effect of
this viral transcription factor on cellular gene expression.
For this, we used the U133A GeneChips (Affymetrix) rep-
resenting 22,277 human genes probes set. Statistical filter-
ing was done to include only genes with a modulation ρ-
value < 0.05 (see materials and methods) and found sim-
ilarly regulated in three independent experiments. As
shown in Table 1, 17 genes were up-regulated and 9 were
down-regulated in the three HeLa-IE63 cell lines relative
to control cells (HeLa-Inv). Gene ontogeny analysis indi-
cated that the predominant categories were signal trans-
duction and transcription.
Real-time RT-PCR experiments were then carried out to
confirm the results obtained from micro-array studies.
RNA levels of 4 down-regulated (RCE1, C3, RAB8B, and
GATA3; Fig. 2A) and four up-regulated (CYFIP2, GPR37,
WIF1, and NELL2; Fig. 2B) genes measured by qRT-PCR
confirmed the micro-array data.
IE63 alters the recruitment of the Human RNA polymerase 
II on the WIF1 and C3 promoters
IE63 was shown to be able to disrupt the transcriptional
pre-initiation complex and to interact with several general
transcription factors such as RNA POL II, TFIIH, and TFIIE
[23]. In order to investigate whether IE63 diminished or
enhanced the RNA POL II binding on endogenous human
promoters, ChIP assays using antibody to RNA POL II
were carried out on promoters either up- (WIF1) or down-
(C3) regulated by IE63. As shown in Fig. 3, IE63 enhanced
the RNA POL II binding on the WIF1 promoter up to 2-
fold (Fig.3A), whereas RNA POL II binding was signifi-
cantly decreased by IE63 on the C3 promoter (Fig.3B).
In conclusion, the results presented above showed that
IE63 could modulate either positively or negatively the
transcription on a restricted number of endogenous pro-
Table 1: Genes induced or repressed in HeLa-IE63 cells compared with control cells (Hela-Inv).
Affimetrix designation Entrez gene no. Fold Induction Gene Symbol Description
Signal transduction
209631_s_at 2861 2.333 GPR37 G protein-coupled recept 37 (endoth recept type B-like)
204712_at 11197 2.192 WIF1 WNT inhibitory factor 1
210095_s_at 3486 1.911 IGFBP3 insulin-like growth factor binding protein 3
203474_at 10788 1.654 IQGAP2 IQ motif containing GTPase activating protein 2
209869_at 150 1.603 ADRA2A Adrenergic, alpha-2A-, recept/adrenergic, alpha-2A-, recept
219210_s_at 51762 0.534 RAB8B Member RAS oncogene family
Transcription
213906_at 4603 1.677 MYBL1 v-myb myeloblastosis viral oncogene homolog (avian)-like 1
209604_s_at 2625 0.548 GATA3 GATA binding protein 3
215685_s_at 1746 0.507 DLX2 distal-less homeo box 2
Immunity
217767_at 718 0.507 C3 complement component 3
Intracellular organelle
212223_at 3423 1.7 IDS Iduronate 2-sulfatase (Hunter syndrome)
203397_s_at 2591 1.579 GALNT3 UDP-N-acetyl-alpha-D-galactosamine(GalNAc-T3)
202843_at 4189 1.56 DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9
205830_at 1047 1.648 CLGN Calmegin
205333_s_at 9986 0.38 RCE1 RCE1 homolog, prenyl protein protease (S. cerevisiae)
211113_s_at 9619 0.588 ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1
Other/Unclassified
215785_s_at 26999 2.59 CYFIP2 Cytoplasmic FMR1 interacting protein 2
221901_at 85352 1.892 KIAA1644 KIAA1644 protein
208567_s_at 3768 1.889 KCNJ12 Potassium inwardly-rectifying channel, subfamily J, member 12
220393_at 51557 1.864 GLULD1 Glutamate-ammonia ligase domain containing 1
203413_at 4753 1.833 NELL2 NEL-like 2 (chicken)
215783_s_at 249 1.67 ALPL Alkaline phosphatase, liver/bone/kidney
212158_at 6383 1.668 SDC2 Syndecan 2
213629_x_at 4494 0.582 MT1F Metallothionein 1F
209946_at 7424 0.579 VEGFC Vascular endothelial growth factor C
211066_x_at 134014 0.559 Protocad Protocadherin gamma subfamily A, B and CBMC Molecular Biology 2007, 8:99 http://www.biomedcentral.com/1471-2199/8/99
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moters and this effect required its proper phosphorylation
by several cellular kinases.
The effect of IE63 on human gene expression is cell-type 
dependent
It has been recently shown that IE63 could modulate a dif-
ferent set of genes when expressed in MRC-5 cells [28]. We
then decided to generate MeWo cells stably expressing
IE63 in order to determine whether the modulation of
gene expression is cell-type dependent. MeWo cells were
then infected with the same lentivirus as above. As
observed in HeLa cells, the proportion of cells expressing
IE63 protein was almost 100% (data not shown). As
shown in Fig. 4A, the expression level of IE63 is similar in
the three independent MeWo cell lines generated. Micro-
array analysis showed that the number of genes affected
by IE63 was much higher in this cell-type than in HeLa
cells (Table 2). Twenty-one genes were up-regulated and
75 genes were down-regulated more than 2-fold in
MeWo-IE63 cells compared to control cells (Table 2).
Gene ontogeny analysis indicated that the predominant
categories were signal transduction, genes involved in
transcription, which were all down-regulated, immunity/
inflammation, chromatin, and 3 members of the heat
shock protein 70 (HSP70) family. Real time RT-PCR
experiments confirmed the results obtained with 2 up-reg-
ulated genes (HLA-DRB1, and MCP-1) and 2 down-regu-
lated genes (TRAF1, and HSPA6) (Fig. 4B).
IE63 modulates gene transcription induced by TNFα
Previous works from our laboratory have shown that tran-
siently expressed IE63 is able to down-regulate several cel-
lular NF-κB-responding genes like IL-8 and IL-6 [23].
Surprisingly, the basal expression level of these genes was
not repressed in our experiments, as demonstrated by
both micro-array analysis (Table 1 and 2) and real-time
RT-PCR (Fig. 5). We also investigated the expression pat-
tern of two other NF-κB-responding genes, ICAM-1 and
IκBα, and we showed that the basal expression of these
genes was not altered by IE63. The fact that IE63 had no
effect on basal expression of some NF-κB responsive genes
may be due to a problem of promoter accessibility linked
to chromatin. In order to assess this issue, we measured
the transcription level of these genes (IL-8, IL-6, ICAM-1,
and IκBα) in IE63 expressing HeLa cells after treatment
with TNFα, a cytokine known to increase chromatin acces-
sibility of several genes. Once HeLa cells were stimulated
by TNFα for increasing times (from 0 to 2 h), it turned out
that the presence of IE63 reduced the TNFα-mediated
expression of IL-8, IL-6, and ICAM-1 (Fig. 6A). Surpris-
ingly, the transcription of IκBα gene was selectively
increased by the presence of IE63 (Fig.6A). This unex-
pected result was confirmed by Western blot analysis. For
this, HeLa cells expressing or not IE63 were treated for
increasing times (from 0 to 2 h) with TNFα at a final con-
centration of 200 U/mL. As shown in Fig. 6B, in control
HeLa cells a complete IκBα degradation could be
observed after 15 min before observing its resynthesis
after 60 min. In IE63 expressing HeLa cells, a complete
IκBα degradation could also be observed 15 min after
TNFα addition, but its resynthesis could be observed as
soon as 30 min demonstrating that the presence of IE63
accelerated the replenishment of the IκBα pool.
The phosphorylation status of IE63 was shown to be cru-
cial for influencing the TNFα-mediated gene transcrip-
RNA polymerase II recruitment on selected cellular genes in  HeLa cells expressing or not IE63 Figure 3
RNA polymerase II recruitment on selected cellular 
genes in HeLa cells expressing or not IE63. ChIP assay 
using RNA polymerase II antibody or unspecific antibody 
(lane 1) was performed on total cell lysates. Real-time PCR 
amplification of a 100 bp fragment from the WIF1 (A), and 
C3 (B) promoter encompassing [59] the transcription initia-
tion site was carried out. ρ-values were calculated using the 
graphpad quickcalcs software [59]: *, significantly different 
from control (Inv ; p-value < 0.05).
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Table 2: Genes induced or repressed in MeWo-IE63 cells compared with control cells (MeWo-Inv).
Affimetrix designation Entrez gene no. Fold Induction Gene Symbol Description
Signal Transduction
204425_at 393 0.50 ARHGAP4 Rho GTPase activating protein 4
204736_s_at 1464 0.50 CSPG4 chondroitin sulfate proteaoglycan 4
206028_s_at 10461 0.50 MERTK  c-mer proto-oncogene tyrosine kinase
206374_at 1850 0.50 DUSP8 dual specificity phosphatase 8
213221_s_at 23235 0.50 KIAA0781 KIAA0781 protein
206359_at 9021 0.38 SSI-3  STAT induced STAT inhibitor 3
202328_s_at 5310 0.33 PKD1 polycystic kidney disease 1 (autosomal dominant)
Transcription
201328_at 2114 0.50 ETS2 avian erythroblastosis virus E26 oncogene homolog 2
213668_s_at 6659 0.50 SOX4  SRY (sex determining region Y)-box 4
213931_at 3398 0.50 ID2 inhibitor of DNA binding 2, dominant negative helix-loop-
helix protein
215012_at 26036 0.47 KIAA0576 KIAA0576 protein
31637_s_at 732801 0.47 Rev-ErbAalpha Rev-ErbAalpha
203873_at 6594 0.44 SMARCA1 Human global transcription activator homologous sequence 
mRNA
202672_s_at 467 0.41 ATF3 activating transcription factor 3
210426_x_at 6095 0.41 RORA Human orphan hormone nuclear receptor RORalpha1 
mRNA
202861_at 5187 0.38 PER1 Homo sapiens period (Drosophila) homolog 1
Immunity/Inflamation
215193_x_at 3125 2.64 HLA-DRB1 MHC class II antigen
216598_s_at 6347 2.46 MCP-1 monocyte chemotactic protein
206569_at 11009 2.14 ST16 Homo sapiens suppression of tumorigenicity 16
211990_at 3113 2.14 HLA-DPA1 MHC class II DPw3-alpha-1 chain mRNA
208894_at 3122 2.00 HLA-DRA MHC class II HLA-DR-alpha
209312_x_at 3123 2.00 HLA-DRB1 HLA-DRB (MHC class II antigen)
206026_s_at 7130 0.50 TNFAIP6 tumor necrosis factor, alpha-induced protein 6
209447_at 23345 0.50 8B7 lymphocyte membrane associated protein
214201_x_at 7916 0.47 D6S51E HLA-B associated transcript-2
207850_at 2921 0.44 GRO3 GRO3 oncogene
217028_at 7852 0.38 CXCR4 receptor CXCR4
205599_at 7185 0.35 TRAF1 TNF receptor-associated factor 1
203665_at 3162 0.35 HMOX1  heme oxygenase (decycling) 1
Intracellular organelle
217452_s_at 8707 3.73 B3GALT2 2-acetamido-2-deoxy-D-glucose3beta- 
galactosyltransferase
205069_s_at 23092 2.83 KIAA0621 KIAA0621 protein
219250_s_at 23767 2.30 FLRT3 FLRT3 (fibronectin leucine rich transmembrane protein 3)
211205_x_at 8394 2.14 PIP5K1A 68 kDa type I phosphatidylinositol-4-phosphate5-kinase 
alpha
205547_s_at 6876 2.00 TAGLN transgelin
204293_at 6448 0.50 SGSH N-sulfoglucosamine sulfohydrolase
209893_s_at 2526 0.50 FUT4 ELAM-1 ligand fucosyltransferase
205830_at 1047 0.38 CLGN Homo sapiens calmegin
207949_s_at 3382 0.33 ICA1 islet cell autoantigen 1 (69 kD)
214341_at 8906 0.02 AP1G2 adaptor-related protein complex 1, gamma 2 subunit
Chromatin
212257_s_at 6595 2.00 SMARCA2 SWISNF related actin dependent regulator of chromatin, sf 
a, mb 2
210387_at 8339 2.00 H2BFA H2B histone family, member A
Heat-Shock
202581_at 3304 0.50 HSPA1B heat shock 70 kD protein 1B
202843_at 4189 0.47 MDG1 microvascular endothelial differentiation gene 1
217911_s_at 9531 0.47 BAG3 BCL2-associated athanogene 3
117_at 3311 0.27 HSP70B HSP70B Human heat-shock protein HSP70B gene
213418_at 3310 0.22 HSPA6 heat shock 70 kD protein 6 (HSP70B)
Other/Unclassified
204730_at 9783 5.66 KIAA0237 KIAA0237 gene productBMC Molecular Biology 2007, 8:99 http://www.biomedcentral.com/1471-2199/8/99
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206021_at 54581 3.03 SCAND2 SCAN domain-containing 2
222108_at 347902 2.83 AMIGO-2 amphoterin-induced protein 2 precursor
218332_at 55859 2.64 HBEX2 hypothalamus protein
214079_at 10901 2.30 SDR2 dehydrogenase/reductase (SDR family) member 2
208282_x_at 57055 2.00 DAZ2 deleted in azoospermia 2
205960_at 5166 2.00 PDK4 Homo sapiens pyruvate dehydrogenase kinase, isoenzyme 4
211814_s_at 9134 2.00 CCNE2 cyclin E2 splice variant 1
202842_s_at 4189 0.50 DKFZp564F18
62
hypothetical protein
222175_s_at 51586 0.50 FLJ00003 FLJ00003 protein
201500_s_at 6992 0.50 PPP1R11 PPP1R11
203045_at 4814 0.50 NINJ1 ninjurin 1
206307_s_at 2297 0.50 FOXD1 forkhead box D1
216594_x_at 1645 0.50 chlordecone  chlordecone reductase homolog
220058_at 79018 0.50 MGC3048 hypothetical protein MGC3048
221213_s_at 54816 0.50 FLJ20086 hypothetical protein FLJ20086
218145_at 57761 0.50 LOC57761 protein kinase domains containing proteinsimilar to 
phosphoprotein C8FW
219401_at 64132 0.50 XT2  xylosyltransferase II
220587_s_at 64223 0.50 GBL G protein beta subunit-like
214782_at 11016626 0.47 FLJ13271 cDNA FLJ13271 fis
214814_at 11684382 0.47 DKFZp564P05
6
cDNA DKFZp564P056
218651_s_at 55323 0.47 FLJ11196 hypothetical protein FLJ11196
219039_at 54910 0.47 FLJ20369 hypothetical protein FLJ20369
221836_s_at 6697854 0.47 FLJ22741 Homo sapiens cDNA: FLJ22741 fis
203431_s_at 9743 0.47 KIAA0712 KIAA0712 gene product
203504_s_at 19 0.47 ABCA1 ATP-binding cassette, sub-family A, member 1
209947_at 9898 0.47 KIAA0144 KIAA0144 gene product
218751_s_at 55294 0.44 FLJ11071 hypothetical protein FLJ11071
215078_at 4914612 0.44 DKFZp564M2
422
cDNA DKFZp564M2422
204623_at 7033 0.44 TFF3 Homo sapiens trefoil factor 3 (intestinal)
209182_s_at 11067 0.44 DEPP decidual protein induced by progesterone
215670_s_at 10434472 0.41 FLJ12782 cDNA FLJ12782 fis
218920_at 54540 0.41 FLJ10404 Homo sapiens hypothetical protein
219747_at 79625 0.41 FLJ23191 Homo sapiens hypothetical protein FLJ23191
204469_at 5803 0.41 PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypeptide 
1
212531_at 3934 0.41 LCN2 Homo sapiens lipocalin 2 (oncogene 24p3)
211030_s_at 13623302 0.38 MGC:10619 clone MGC:10619
221959_at 10032854 0.38 FLJ22488 FLJ22488 fis
209160_at 8644 0.38 c-hluPGFS Homo sapiens mRNA for hluPGFS
212839_s_at 6738 0.38 SSA2 Sjogren syndrome antigen A2 (60 kD, ribonucleoprotein 
autoantigen SS-ARo)
218864_at 7145 0.35 PRO0929 PRO0929 mRNA
220123_at 80255 0.35 FLJ22004 hypothetical protein FLJ22004
207992_s_at 272 0.35 AMPD3 adenosine monophosphate deaminase (isoform E)
213158_at 1523376 0.33 DKFZp586B21
1
cDNA DKFZp586B211
213445_at 23144 0.33 KIAA0150 KIAA0150 protein
219797_at 11320 0.33 MGAT4A mannosyl-glycoprotein beta-acetylglucosaminyltransferase
219935_at 11096 0.31 ADAMTS5 disintegrin-like and metalloprotease with thrombospondin 
type 1 motif
213156_at 12761337 0.29 DKFZp586B21
1
cDNA DKFZp586B211
216006_at 24694 0.27 24694 clone 24694
206273_at 10650 0.27 HFL-EDDG1 erythroid differentiation and denucleation factor 1
218790_s_at 55217 0.19 FLJ10727 hypothetical protein FLJ10727
211037_s_at 13623420 0.07 MGC:13124 clone MGC:13124
210709_at 7770220 0.06 PRO2710 PRO2710 mRNA
209613_s_at 125 0.02 ADH2 alcohol dehydrogenase beta-1 subunit
217177_s_at 5262528 0.01 FLJ13658 cDNA DKFZp564N2216
Table 2: Genes induced or repressed in MeWo-IE63 cells compared with control cells (MeWo-Inv). (Continued)BMC Molecular Biology 2007, 8:99 http://www.biomedcentral.com/1471-2199/8/99
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Relative expression of selected cellular genes in MeWo-IE63  cells versus control cells Figure 4
Relative expression of selected cellular genes in MeWo-
IE63 cells versus control cells. (A) Cells were lysed in radi-
oimmunoprecipitation assay buffer and used for immunoblot-
ting with mouse monoclonal antibody to the ORF63 protein 
or with rabbit polyclonal antibody to the GFP. (B) mRNA 
levels (TRAF1, HSPA6, MCP-1, and HLA-DRB1) were deter-
mined by quantitative real-time PCR and normalized using 
the β2-microglobuline transcripts. Experiments were done at 
least in triplicate. Differences (n-fold) between samples were 
calculated using the standard-curve method and the 2-∆Ct 
method. ρ-values were calculated using the graphpad quick-
calcs software [59]: *, significantly different from control (Inv 
; p-value < 0.05).
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Relative basal expression of IL-8, IL-6, ICAM-1 and IκBα  genes in HeLa-IE63 cells compared to control cells Figure 5
Relative basal expression of IL-8, IL-6, ICAM-1 and IκBα 
genes in HeLa-IE63 cells compared to control cells. 
mRNA levels (IL-8, IL-6, ICAM-1, and IκBα) were deter-
mined by quantitative real-time PCR in unstimulated HeLa 
cells expressing or not IE63 and normalized using the β2-
microglobuline transcripts. Experiments were done at least 
in triplicate. Differences (n-fold) between samples were cal-
culated using the standard-curve method and the 2-∆Ct 
method. ρ-values were calculated using the graphpad quick-
calcs software [59] : **, not significantly different from con-
trol (Inv ; p-value ≥ 0.05).
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Relative expression of IL-8, IL-6, ICAM-1 and IκBα genes in HeLa cells expressing IE63, IE63-S224/T222A, and IE63-Full versus  control cells stimulated or not with TNFα Figure 6
Relative expression of IL-8, IL-6, ICAM-1 and IκBα genes in HeLa cells expressing IE63, IE63-S224/T222A, and IE63-
Full versus control cells stimulated or not with TNFα. HeLa cells expressing IE63 wild-type, IE63-S224/T222A, IE63-Full or 
IE63 in inverted orientation (Inv, control) were treated for increasing times (from 0 to 2 h) with TNFα at a final concentration 
of 200 U/mL. (A) Total RNA extracts were isolated and analyzed by Real-time RT-PCR using primers for the IL-8 mRNA, IL-6 
mRNA, ICAM-1 mRNA, and IκBα mRNA. (B) The IκBα degradation. HeLa cells expressing IE63wt or control cells were 
treated for increasing times (from 0 to 2 h) with TNFα (200 U/mL). IκBα degradation was followed by Western Blotting on 
total cellular extracts. β-actin Western Blotting detection was used as loading control (lower panel). ρ-values were calculated 
using the graphpad quickcalcs software [59]: *, significantly different from control (Inv ; p-value < 0.05) ; **, not significantly dif-
ferent from control (Inv ; p-value ≥ 0.05).
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tion. For this, we compared IL-8, IL-6, ICAM-1, and IκBα
RNA levels in HeLa cells expressing either IE63, or the two
mutated forms (IE63-S224/T222A, and IE63-Full). As it
shown in Fig. 6A, when phosphorylation is suppressed by
alanine substitution, IE63 did not significantly modulate
the TNFα-induced gene transcription, demonstrating the
importance of correct phosphorylation of IE63 for this
property.
IE63 perturbs chromatin structure and NF-κB binding on 
the TNFα modulated gene promoters
To go one step further in the understanding of the mech-
anism by which IE63 modified IL-8, ICAM-1, and IκBα
inducibility by TNFα, chromatin immuno-precipitation
assays (ChIP) were carried out. Histone acetylation and
histone deacetylase (HDAC) removal were often associ-
ated with an increased chromatin accessibility at NF-κB-
responsive promoters [29]. Using an antibody directed
against the acetylated lysine 9 of histone H3 in ChIP assay,
it was obvious that IE63 expression led to opposite effects:
it reduced IL-8 and ICAM-1 promoters accessibility
whereas it increased IκBα promoter accessibility upon
TNFα (Fig.7A). The decreased accessibility of the IL-8 and
ICAM-1 promoters mediated by IE63 correlated very well
with a recruitment of HDAC3 while the reverse was
observed with IκBα promoter (Fig. 7B).
Since results from our laboratory (El Mjiyad et al., submit-
ted) showed that VZV is able to interfere with the immune
response by inhibiting NF-κB binding to specific promot-
ers, we investigated the in vivo recruitment of the NF-κB
subunit p65 on IL-8, ICAM-1, and IκBα promoters. HeLa-
IE63 and control cells (HeLa-Inv) were treated during
increasing times (from 0 to 2 h) with TNFα (200 U/mL).
HDAC3, NF-κB recruitment, and Histone H3 acetylation on selected cellular genes in HeLa cells expressing IE63 versus con- trol cells Figure 7
HDAC3, NF-κB recruitment, and Histone H3 acetylation on selected cellular genes in HeLa cells expressing IE63 ver-
sus control cells. (A, and B) HeLa cells were treated for one hour with TNFα (200 U/mL) and ChIP assay analysis was per-
formed using an antibody specific of the K9 acetylated form of the histone H3 (A) and the histone deacetylase HDAC3 (B). An 
unspecific antibody (Flag) was used for evaluating specificity. (C) HeLa cells were treated for increasing times (from 0 to 2 h) 
with TNFα at a final concentration of 200 U/mL. ChIP assay using p65 antibodies was performed on total cell lysates. Real-time 
PCR amplification of a 100 bp fragment from the IL-8, ICAM-1 and IκBα promoter encompassing the proximal NF-κB site was 
carried out. ρ-values were calculated using the graphpad quickcalcs software [59] : *, significantly different from control (Inv ; p-
value < 0.05) ; **, not significantly different from control (Inv ; p-value ≥ 0.05).
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After chromatin immunoprecipitation using specific anti-
bodies to p65, quantitative PCR amplification of a region
of 100 bp surrounding the NF-κB site(s) on the IL-8,
ICAM-1 and IκBα promoters was carried out. As shown in
Fig. 7C, the cells treatment during one hour with TNFα
induced a 3- and 25-fold increase of p65 binding at the
NF-κB proximal site of the IL-8, and ICAM-1 promoter,
respectively. In HeLa-IE63 cells, this increase was signifi-
cantly diminished. We then looked at IκBα promoter, and
it turned out that the presence of IE63 increased p65 bind-
ing (Fig. 7C). Indeed, after one hour of TNFα treatment, a
3-fold increase of p65 binding was observed in control
cells, whereas in IE63 expressing HeLa cells, a 10-fold
increase was observable, demonstrating again that IE63
enhanced p65 recruitment at the IκBα promoter.
Discussion
IE63 is of particular interest in Varicella Zoster Virus
pathogenesis since it is abundantly expressed during acute
as well as latent infection [15]. The activity of IE63 as a
potential transcriptional regulator has been subject to
controversy for years, being described either as an activa-
tor or a repressor of transcription [17,22-27].
To clarify this issue, the first part of this work was devoted
to the examination of the effects of IE63 on cellular gene
expression using a whole genome micro-array analysis in
HeLa and MeWo cells stably expressing IE63. The main
results obtained in this study can be summarized as fol-
low: (i) IE63 alone affected on a cell-type mode the tran-
scription of a limited number of human genes, including
genes implicated in signal transduction, transcription,
immunity, and heat-shock signalling. (ii) IE63 expression
led to an inhibition or an increase of RNA POL II binding
on the down- and up-regulated promoters tested here.
(iii) In HeLa cells, the correct phosphorylation of the pro-
tein is a crucial event for its regulatory properties on
endogenous promoters.
Expression of IE63 protein by a lentivirus influenced the
transcription of relatively few cellular genes in HeLa (26
genes) and MeWo cells (106 genes). Previous micro-array
studies performed with VZV-infected cells indicated that
VZV was able to modify the expression of a variable
number of genes depending on the cell type used [30,31].
Comparative micro-array analysis of IE63 expressing cells
demonstrated many differences in depending on the cell
type considered. Indeed, Hoover et al. [28] showed that,
in human diploid fibroblasts (MRC-5), 71 genes of
approximately 33,000 genes were up-regulated and 23
were down-regulated by IE63 protein. In human neurob-
lastoma (SKNSH), no significant differences in the expres-
sion level of cellular genes was found between control and
IE63 expressing cells [28].
Several explanations might be proposed to explain these
differences in response to IE63. First, as we and other have
already shown, IE63 is a heavily phosphorylated protein
and the phosphorylation pattern is cell-type dependent
[17,24,25,32]. Another reason may be found in the chro-
matin context and promoter accessibility that may be dif-
ferent in the two cell types investigated. In the various
works cited above, IE63 was expressed in several cellular
backgrounds whose gene expression is likely to be differ-
ently affected by growth in cell culture. A last explanation
is the viral vector used. Hoover et al. measured the effect
of IE63 as soon as two days after cell infection with an
adenovirus [28] whereas lentivirus was used in our work.
It could be conceivable that infection mediated by adeno-
virus increased by itself chromatin accessibility allowing
IE63 to access to a greater number of promoters, and then
having a higher influence on cellular genes expression.
It must also be pointed out that the comparison between
IE63 expression in MRC5 [28] and MeWo cells exhibited
several common features. Histone H2 coding genes were
up-regulated in both cell types while Heat Shock Protein
70 (hsp70) and TNFα-induced protein (TNFAIP) genes
were down-regulated. While several viruses (including
Herpesvirus and Adenovirus) have been reported to
induce hsp70 genes [33-36], it is not clear yet why IE63
specifically and drastically down-regulated the members
of this family.
Among the rather limited list of genes regulated in HeLa
cells mediated by IE63, the down-regulation of the gene
encoding the component protein 3 could be noticed. The
complement system comprises several dozen proteins cir-
culating in serum, or attached to cell surfaces, and orches-
trating three distinct cascades (classical, alternative, and
lectin pathways) into antimicrobial effector activities that
range from the opsonization of foreign particles, the
recruitment of phagocytes, to the lysis of infected cells
[37]. The complement cascade is under tight cellular con-
trol by host inhibitor proteins, and it is perhaps not sur-
prising that VZV has an inhibitory effect as an anti-
complement defence system. Some viruses, for example
HCMV, induce the expression of cellular complement
inhibitors like DAF at the surface of infected cells [38]. The
Epstein-Barr virus (EBV) also has complement regulatory
activity against C3 [39]. Different studies have shown that
HSV-1 and -2 gC proteins offer protection against viral
neutralization mediated by complement [40,41].
When gene expression profiles obtained in this paper are
compared to micro-array data obtained by the analysis of
VZV infected cells [30,31], there are several global similar-
ities that showed up, and among them, genes implicated
in immunity/inflammation, signal transduction, and
transcription in T cells, or in fibroblasts, as well as in VZV-BMC Molecular Biology 2007, 8:99 http://www.biomedcentral.com/1471-2199/8/99
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infected skin xenografts. These classes of genes are also
influenced when IE63 is expressed alone. For instance,
among genes implicated in immunity/inflammation,
TRAF (TNF Receptor-Associated Factor) genes are down-
regulated in VZV-infected T cells as well as in IE63 express-
ing MeWo cells. Concerning signal transduction, two Ras
oncogene family members and genes coding for G protein
receptors were also down-regulated in both cases. Our
work demonstrated that MCP-1 gene expression was stim-
ulated by IE63, and this result is in accordance with what
was shown by Jones et al. in VZV-infected cells [31].
Another important finding of this work was the demon-
stration that IE63 can differentially affect the TNF-induci-
bility of NF-κB regulated genes. The relevant results
obtained here are: (i) in TNFα-stimulated cells, the expres-
sion of IL-8, IL-6, ICAM-1, and IκBα genes was affected by
IE63 in a promoter-dependent manner, (ii) the phospho-
rylation status of the protein influenced these regulatory
properties, (iii) the effects of IE63 were correlated with a
modification of chromatin structure, and finally (iv) IE63
was able to modulate NF-κB binding on the tested pro-
moters.
We have been able to show that TNFα treatment increases
chromatin accessibility in the proximal area of the tested
promoters as demonstrated by histone H3 acetylation and
the inhibition of HDAC3 binding. Furthermore, the pres-
ence of IE63 modified chromatin in a different extent
depending on the considered promoter. Unexpectedly,
IE63 led to inhibition of chromatin accessibility mediated
by TNFα on IL-8 and ICAM-1 genes, and to an increased
accessibility in the context of the IκBα promoter. The inhi-
bition of IL-8, and ICAM-1 gene expression could very
well be a consequence of the induction of IκBα, since this
protein is an inhibitor of NF-κB [42,43].
NF-κB plays a central role in the innate and adaptive
immune response. The activation of this factor during
early stages of viral infection leads to the expression of
several immune response genes; such as pro-inflamma-
tory cytokines (IFN-β, TNF-α, IL-6, IL-8), chemokines
(RANTES) and adhesion molecules (ICAM-1, VCAM-1).
NF-κB also strongly induces MHC-I and CD80/86 expres-
sion on antigen presenting cells, thus increasing T-cell
activation [44]. NF-κB activation appears to be necessary
for optimal replication of HSV-1 and HCMV early in infec-
tion, since it has been shown that blocking the NF-κB
pathway decreased viral yields and inhibited the activa-
tion of several viral genes harbouring NF-κB response ele-
ments in their promoter [45,46]. A model of this
interdependence between HCMV and NF-κB has been
generated by Montag et al. [47]. In contrast, the lack of
functional NF-κB response elements in the promoters of
VZV IE genes allows suspecting that VZV replication cycle
could be NF-κB independent. VZV may need to directly
interfere with the NF-κB signalling in order to avoid
downstream effects of NF-κB activation. Likely, NF-κB
inhibition properties of VZV could at least in part be
mediated by IE63. Such a modulation mechanism of NF-
κB has already been demonstrated with HCMV. Indeed,
Taylor et al. have shown that HCMV Immediate Early pro-
tein IE86 can suppress virus-induced pro-inflammatory
cytokines transcripts expression by efficiently blocking the
binding of NF-κB to cellular NF-κB responding genes [48].
Surprisingly it has been shown that VZV specifically
induced interleukin-6 in human monocytes via TLR2-
dependent activation of NF-κB [49]. Moreover Rahaus et
al. have demonstrated that infection by VZV caused a sig-
nificant increase in activation of JNK/SAPK in the early
phase of infection and an increase in activation of p38/
MAPK in the later phase. Subsequent cascades to induce
pro-inflammatory responses were activated whereas cas-
cades to activate apoptotic events were not [50]. This sug-
gests that activation of stress pathways by VZV infection
represents a finely regulated system that activates cellular
transcription factors for transregulation of VZV-encoded
genes, but prevents activation of cellular defence mecha-
nisms [50].
The observation that IκBα transcription was stimulated
when IE63 expressing cells were treated with TNFα sug-
gests that the strategy by which VZV, may be via IE63,
inhibits the NF-κB pathway may protect VZV-infected
cells from antiviral responses induced by exogenous pro-
inflammatory cytokines, many of which act through NF-
κB signalling pathways.
One of the main information brought by this work is the
capacity of the IE63 to exert epigenetic effects on NF-κB
regulated promoters. Similar effects on chromatin have
been observed with other α-Herpsvirus. Indeed, in HSV-1
infected cells, ICP0, the homologue of VZV ORF61 pro-
tein, has been shown to block viral genes silencing by
interacting with HDAC1 [51]. Moreover, the US3 kinase
(the VZV ORF66 kinase homolog) can also block this
silencing in a mechanism distinct from that of ICP0
[52,53]. It has been demonstrated that during lytic infec-
tion HSV-1 is associated with histone bearing modifica-
tions that correlate with active transcription [51], ICP0
may be responsible for this chromatin permissiveness.
Concerning the Bovine Herpesvirus 1 (BHV-1), it has
been shown that bICP0 can associate with HDAC1 to
relieve HDAC1-mediated repression of viral gene tran-
scription [54]. Furthermore, this protein was able to inter-
act with p300/CBP (CREB Binding Protein) and this
interaction cooperate to enhance viral gene expression
and may interfere with antiviral signalling [55].BMC Molecular Biology 2007, 8:99 http://www.biomedcentral.com/1471-2199/8/99
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Conclusion
In conclusion, this work clearly demonstrated that stable
expression of IE63 in two cellular backgrounds only
affected the basal expression of a rather limited number of
genes while it differentially modulated the TNFα-induci-
bility of several NF-κB-regulated genes. While the molec-
ular mechanisms governing these effects are not
established yet, it can be suspected that IE63 is a major
player in the complex interplay between VZV and the host
immune system.
Methods
Cells lines
MeWo cells, a continuous human melanoma cell line
(ECACC93082609), were grown in EMEM (Biowhittaker)
supplemented with 10% foetal bovine serum (FBS, biow-
hittaker), 1% L-glutamine, and 1% non-essential amino
acids (NEAA, GibcoBRL).
HeLa cells, human epithelial cells from a fatal cervical car-
cinoma transformed by human papillomavirus 18
(ATCC-CCL-2), were cultivated in Eagle's Modified Essen-
tial Medium (EMEM, Biowhittaker) supplemented with
10% foetal calf serum (FCS, Biowhittaker), and 1% L-
glutamine.
293FT cells, derived from 293 cell line established from
primary embryonic human kidney transformed with
sheared human adenovirus type 5 DNA, were grown in
Dulbecco's Modified Eagle's Medium (DMEM, Biowhit-
taker) supplemented with 10% FBS, 1% L-glutamine, 1%
NEAA, and 1% Penicillin/Streptavidine (P/S).
Lentiviruses in which the ORF63 has been cloned in the
sense (Lenti-IE63), or in the anti-sense orientation (Lenti-
Inv, control) were produced by transient calcium phos-
phate co-transfection of 293FT cells with the plasmid car-
rying the IE63 gene (pTRIP-EFIα-ORF63-IRES-EGFP
[56]), pCMV8.91 (a kind gift from Dr. D. Trono [57]) and
pVSV-G (a kind gift from Dr. T. Friedmann [58]) as previ-
ously described [56]. A similar procedure was followed to
generate a lentivirus in which the ORF63 was mutated
either at S224/T222A (Lenti-IE63-S224/T222A), or on all
the target residues of CK1, CK2, and CDK1, i.e. S15A,
S150A, S157A, S165A, T171A, S173A, S181A, S185A,
S186A, S197A, S200A, T201A, S203A, T222A, S224A, and
T224A (Lenti-IE63-Full) [24]. All of these constructs con-
tain the gene encoding the enhanced green fluorescent
protein (EGFP). Lentivirus concentrations were deter-
mined by measuring the HIV-1 p24 capsid protein. The
viral titers were measured on the CEMx174 cells and
expressed in TU/mL (Transduction Unit/mL).
HeLa and MeWo cells were plated at 5 × 105 cells/mL and
the lentiviral particles were added at the concentration of
500 ng/mL of viral p24. After 12h, cells were washed and
cultured for 72 h. EGFP expression was confirmed by flow
cytometry analysis. This procedure allowed us to generate
four HeLa cell lines, i.e. HeLa-IE63, HeLa control cells
(HeLa-Inv), HeLa-IE63-S224/T222A, and HeLa-IE63-Full,
and two MeWo cell lines, MeWo-IE63, and control cells
(MeWo-Inv).
Antibodies and reagents
TNFα was purchased from Roche and used at a final con-
centration of 200 U/mL. The antibodies used in this work
(Western blot analysis and immunofluorescence) are
directed against IE63 (produced by Dr. S. Bontems, Uni-
versity of Liège, Belgium), Green Fluorescent Protein
(GFP) (Rabbit polyclonal, 1/1000 ; Tebu Bio SC-8334),
p65 (Rabbit polyclonal, 1/1000 ; Tebu Bio SC-372), IκBα
(Mouse monoclonal, 1/400 ; kind gift from Ron Hay,
Scotland), β-Actin (Mouse monoclonal, 1/1000 ; Sigma),
H3AcK9 (Mouse monoclonal, 1/1000 ; Upstate Cell Sign-
aling), HDAC3 (Mouse monoclonal, 1/1000 ; Upstate
Cell Signaling), Histone H3 (Mouse monoclonal, 1/500 ;
Abcam), and Human RNA polymerase II (Rabbit polyclo-
nal, 1/200 ; Tebu Bio).
Immunofluorescence
HeLa and MeWo control cells or expressing wild-type or
mutated IE63 were seeded on coverslides into 10-mm
dishes and grown in EMEM (Biowhittaker) supplemented
with 10% FBS (Biowhittaker) and 1% L-glutamine. Forty-
eight hours post-seeding, the cells were fixed with 4% (w/
v) paraformaldehyde/PBS for 10 min at room tempera-
ture and 20 min at 37°C. After washing with PBS, cells
were permeabilized with PBS containing 0.1% Triton X-
100 for 10 min at room temperature and 20 min at 37°C.
Cells were then incubated with monoclonal mouse anti-
63 antibody in PBS +1% fetal bovine serum (FBS) for 1 h
at 37°C. After washing with PBS and FBS (1%), cov-
erslides were incubated with a Texas Red- conjugated anti-
mouse secondary antibody (1/1000; Molecular Probes)
for 1 h at 37°C. Following a water wash, cells were
observed by fluorescent microscopy (Nikon).
Western Blot analysis
HeLa or MeWo cells expressing or not wild-type or
mutated IE63 were lysed in radioimmunoprecipitation
assay buffer (10 mM Tris-HCl pH 8, 100 mM NaCl, 1 mM
EDTA, 1% NP-40, 0.5% SDS) containing complete pro-
tease inhibitor cocktail (Roche), and 5 µg of proteins were
separated on a 10% SDS-polyacrylamide gel. Proteins
were transferred to nitrocellulose and detected with a
mouse monoclonal anti-63 antibody. Western Blot analy-
sis of IκBα degradation was done using a mouse mono-
clonal antibody directed against IκBα (kind gift from Ron
Hay, Scotland) and a secondary horseradish peroxidase-
conjugated rabbit anti-mouse antibody (Dako A/S). West-BMC Molecular Biology 2007, 8:99 http://www.biomedcentral.com/1471-2199/8/99
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ern Blot using antibody directed against β-actin was used
as loading control.
Regulatory properties test
Transient transfection studies were carried out with HeLa
cells (HeLa-IE63 and HeLa-Inv) seeded into 35-mm diam-
eter 6-well cluster dishes using the FuGENE6 transfectant
reagent (Roche). The plasmid pPol-luc, where the Firefly
luciferase gene is under the control of the VZV DNA
polymerase gene promoter [25], was used as reporter vec-
tor. The same quantity of each plasmid was transfected in
each experiment. Twenty-four hours post-transfection,
luciferase assays were performed using "Luciferase
Reporter Gene Assay, High Sensitivity" kit (Roche) accord-
ing to the manufacturer's instructions. For each experi-
ment, the concentration of proteins was measured to
normalize the results. Data from luciferase assays were
collected from six independent transfection experiments.
ρ-values were calculated using the graphpad quickcalcs
software [59].
Human gene micro-array analysis
Cells expressing or not wild-type or mutated IE63 were
cultivated as described above then harvested and stored in
RNA Later (Qiagen) at -70°C. Three independent experi-
ments were performed, and the cell pellets were all proc-
essed in parallel. Total RNA was extracted from the cell
pellets using the Rneasy mini kit (Qiagen). Synthesis of
double-stranded DNA, in vitro transcription of biotin-
labelled RNA, and fragmentation of labelled RNA were
performed using the Genechip One-Cycle Target Labeling
and Reagents kit (Affymetrix). The cRNA were then
hybridized to U133A GeneChips (Affymetrix). The data
generated from the three independent experiments were
analyzed using the MSCL Analyst's Toolbox [60]. Affyme-
trix MAS5.0 signal values were retrieved, and a SSG trans-
formation was applied. Only the significant differences
based on ρ-values retrieved from three independent
experiments were considered further. Comparisons were
done using a one-way analysis of variance with trans-
formed normalized data.
Real-time PCR
Real-time PCR amplification was performed using 10 ng
of each purified cDNA. The primers used were designed
using the software Primers Express™ and were obtained
from Eurogentec (Table 3).
PCRs were run on an ABI 7700 instrument with the SYBR
Green Master Mix (Applied Biosystems) and data were
analyzed using Sequence Detector software (Applied Bio-
systems). Results were normalized using the β2-
microglobulin transcripts. Experiments were done at least
in triplicate. Differences (n-fold) between samples were
calculated using the standard-curve method and the 2-∆Ct
method [61]. ρ-values were calculated using the graphpad
quickcalcs software [59].
Chromatin Immuno-precipitation assay
The ChIP assays were carried following the Upstate Cell
Signalling protocol. In short, DNA was sonicated during
twenty minutes (alternatively 30s of sonication followed
by 30s of rest). The protein A Agarose beads (Pierce) were
saturated with Herring Sperm DNA (Sigma-aldrich), 1 µg
DNA/20 µL protein A Agarose. All ChIP assays were per-
formed at least three times. qPCR targeting the promoter
Table 3: 
Gene Forward primer Reverse primer
C3 5'-gagccaccgaaaaatggaatc-3' 5'-gatccctttcttgtccgacatg -3'
GATA3 5'-tgaagcctaaacgcgatggata-3' 5'-ggtccagattcagtggttggaa-3'
RCE1 5'-tggagttgcccattttcacc-3' 5'-aagcagtgtaggcaccgaagac-3'
RAB8B 5'-cgccttcaacaccaccttcat-3' 5'-cgctgtgtcccatatctgaagc-3'
WIF1 5'-tggcagatccaaccgtcaat-3' 5'-tgccaccccatcctgtttt-3'
CYFIP2 5'-tccgagaggccaatcacaat-3' 5'-cgcacaaaacggttagtggac-3'
NELL2 5'-gcccagatcttaatcgcacct-3' 5'-gcttggctgatgttttggct-3'
GPR37 5'-gtcatgtgtctgtccgtggtga-3' 5'-ttggagatgctccgcatgtag-3'
KCNJ12 5'-tttctggtgtcgcccatca-3' 5'-ccaggatgaccacgatctcaa-3'
HSP70 5'-agcagacgcagatcttcacca-3' 5'-aagcgccccaacagattgt-3'
ICAM1 5'-agaccttagcgcggtgtaga-3' 5'-agtagcagaggagctcagcg-3'
IL8 5'-gggccatcagttgcaaatc-3' 5'-ttccttccggtggtttcttc-3'
IL6 5'-aagcacactttccccttcc-3' 5'-ctatcgttcttggtgggctc-3'
IκBα 5'-ccaaccagccagaaattgct-3' 5'-tctcggagctcaggatcaca-3'
TRAF1 5'-gctttttattgttcccacggct-3' 5'-actcgctaggccagaccttcat-3'
HSPA6 5'-ccattgacgctggtgtctttg-3' 5'-cgccggaattcttccatga-3'
MCP1 5'-tctcgcctccagcatgaaagt-3' 5'-gcattgattgcatctggctga-3'
HLA-DRB1 5'-cccagtactggaacagccagaa-3' 5'-tgcactgtgaagctctcaccaa-3'
β2-microglobuline 5'-gagtatgcctgccgtgtg-3' 5'-aatccaaatgcggcatct-3'BMC Molecular Biology 2007, 8:99 http://www.biomedcentral.com/1471-2199/8/99
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region of each gene were performed on the immunopre-
cipitated DNA. The primers used were designed using the
software Primers Express™: ICAM-1-FW (5'-cccgattgctt-
tagcttggaa-3') and ICAM-1-RV (5'-ccggaacaaatgctgcagttat-
3'), IL-8-FW (5'-gccatcagttgcaaatcgtg-3') and IL-8-RV (5'-
agtgctccggtggctttt-3'); IκBα-FW (5'-cgctcatcaaaaagttccctg-
3') and IκBα-RV (5'-ggaatttccaagccagtcagac-3'). For unspe-
cific binding to the beads, treated cells extracts were incu-
bated with 2 µg of unspecific antibody (Flag, Sigma-
aldrich). The following antibodies were used: p65,
H3AcK9, HDAC3, Histone H3, and Human RNA
polymerase II. Data were analysed using AbiPrism 7000
Sequence Detection System Software. Ct values obtained
were normalized following Livak et al. [61]. ρ-values were
calculated using the graphpad quickcalcs software [59].
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